Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 4/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 5/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.49 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28875089 | 0.92 | KDM4E (0.61) | KDM4EALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL22097725 | 0.89 | HCAR3 (0.60) | PLK1CISD1HCAR3KDM6BKDM4C | |
| SCHEMBL22097710 | 0.86 | KDM4E (0.64) | KDM4EALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL22097708 | 0.83 | HCAR3 (0.60) | PLK1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL13597043 | 0.82 | KDM4E (0.51) | PLK1KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL9402438 | 0.81 | MAPT (0.67) | KDM4EALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL3781973 | 0.81 | PLK1 (0.62) | PLK1CISD1HCAR3KDM6BKDM4C | |
| SCHEMBL3973709 | 0.80 | HCAR3 (0.56) | PLK1CISD1HCAR3 | |
| SCHEMBL11258578 | 0.80 | MAPT (0.55) | PLK1KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL27972972 | 0.80 | KDM6B (0.55) | PLK1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786890-B2 | Photo-redox titanium containing organic frameworks and methods of making and use thereof | FLORIDA STATE UNIVERSITY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20200188896-A1 | PHOTO-REDOX TITANIUM CONTAINING ORGANIC FRAMEWORKS AND METHODS OF MAKING AND USE THEREOF | NATIONAL SCIENCE FOUNDATION | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786890-B2 | Photo-redox titanium containing organic frameworks and methods of making and use thereof | PPOX, PPIF, CYBB | PLK1 4218/4885KDM4E 2531/4885ALDH1A1 616/4885 |
| US-20200188896-A1 | PHOTO-REDOX TITANIUM CONTAINING ORGANIC FRAMEWORKS AND METHODS OF MAKING AND USE THEREOF | PPOX, PPIF, CYBB | PLK1 4218/4885KDM4E 2531/4885ALDH1A1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.